BioGend Therapeutics Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
November 11, 2022 at 01:14 am IST
Share
BioGend Therapeutics Co., Ltd. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was TWD 9.57 million compared to TWD 2.02 million a year ago. Net loss was TWD 52.04 million compared to TWD 39.24 million a year ago. Basic loss per share from continuing operations was TWD 0.5 compared to TWD 0.39 a year ago. Diluted loss per share from continuing operations was TWD 0.5 compared to TWD 0.39 a year ago.
For the nine months, sales was TWD 20.45 million compared to TWD 4.46 million a year ago. Net loss was TWD 131.14 million compared to TWD 124.34 million a year ago. Basic loss per share from continuing operations was TWD 1.27 compared to TWD 1.23 a year ago. Diluted loss per share from continuing operations was TWD 1.27 compared to TWD 1.23 a year ago.
BIOGEND THERAPEUTICS CO., LTD. is a medical equipment company mainly engaged in the development of biological aggregate. The Company is mainly engaged in the development and research of high-grade bone filling materials and knee cartilage repair related medical equipment. The Company's main products are BiG-001 which used for long bone biological aggregate, BiG-006 that used for lumbar interbody fusion biological bone, as well as BiG-009.